Ibex Decision Support
Empower pathologists to make quicker and more accurate diagnosis with state-of-the-art decision-support tools
From the press
Dr. Lal PathLabs to deploy the Galen™ platform, supporting pathologists with multi-tissue, AI-driven insights in real time
Read More
From the press
Kantonsspital Baselland to deploy the AI-powered Galen™ platform, helping pathologists improve accuracy and efficiency during primary cancer diagnosis
Read More
From the press
Roche announces that it has entered an agreement with Ibex Medical Analytics, a global leader in artificial intelligence (AI)-based cancer diagnostics.
Read More
From the press
Ibex announces the appointment of Douglas Clark, MD, pathologist and distinguished healthcare executive, as its Chief Medical Officer, Americas, and that Joseph Mossel, its co-founder and CEO, is relocating to the United States to lead the company’s expansion in North-America.
Read More
From the press
Galen™ Gastric is deployed at Maccabi Healthcare Services and helps pathologists improve accuracy and efficiency of cancer diagnosis in routine practice
Read More
From the press
Alverno will deploy Ibex’s AI-powered Galen™ platform, supporting pathologists in improving the quality of cancer diagnosis
Read More
From the press
Ibex and Unilabs agree to implement Ibex’ AI platform in Europe. Unilabs is the first pan-European diagnostics provider to deploy Ibex’ multi-tissue AI-powered Galen™ platform,.
Read More
From the press
Sana Kliniken Berlin-Brandenburg will deploy Ibex’s AI-powered Galen™ platform, helping pathologists provide accurate diagnosis and improved care for cancer patients
Read More
From the press
Ibex’s Galen™ AI-powered platform is recognized by the FDA as breakthrough technology with the potential to more effectively diagnose cancer
Read More
From the press
Ibex’s Galen™ Breast solution demonstrates very high accuracy in detecting multiple types of breast cancer in a blinded study, supporting pathologists to provide accurate diagnosis, enhanced lab efficiency and quality control
Read More
Ibex has been playing an important role in advancing AI-based technologies in pathology and is the first company to implement an AI-driven diagnostic system in routine clinical use. I am a huge advocate of the work of this company.
Sylvia L. Asa, MD, MPH
Former USCAP President and Chief Pathologist at UHN Toronto
I am deeply impressed with the Ibex Second Read system and with the performance of its algorithms, as well as with how quickly the Ibex team was able to deploy a system and integrate it into the routine clinical workflow of a large pathology institute. This disruptive technology is a game-changer.
Daniel Val Garijo, MD
Pathologist, Laboratoire National de Santé, Luxembourg
I’m extremely happy to be collaborating with Ibex on transforming cancer diagnostics – and thrilled to have deployed the Ibex Second Read system at Maccabi, rendering the Maccabi pathology institute the first in the world to deploy such a system in our routine workflow, and the first to demonstrate the value of AI in reversing a missed cancer diagnosis in real time.
Prof. Varda Shalev, MD, MPH
Managing Director, Morris Kahn & Maccabi Research and Innovation Institue at Maccabi Health care Services
The advent of digital pathology enables the implementation of AI-driven technologies to ensure more accurate and rapid cancer diagnosis in pathology institutes. We believe that systems such as the one developed by Ibex have an important role in advancing routine anatomic pathology practice. We will be assessing the performance of the Ibex Second Read system to determine its potential for implementation at UPMC.
